CytomX Therapeutics Inc (CTMX) — Capital Reinvestment Ratio

Latest as of March 2023: 0.01x

CytomX Therapeutics Inc (CTMX) has a Capital Reinvestment Ratio of 0.01x as of March 2023, meaning it reinvests 0% of its operating cash flow ($9.35 Million) in capital expenditures ($48.00K). Check CytomX Therapeutics Inc (CTMX) tangible equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.01x
Capex / Operating Cash Flow

Operating Cash Flow

$9.35 Million
USD

Capital Expenditures

$48.00K
USD

Data as of

Mar 2023
Most recent filing

CytomX Therapeutics Inc Capital Reinvestment Ratio (2014–2020)

This chart tracks CytomX Therapeutics Inc's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see CytomX Therapeutics Inc cash flow conversion.

Annual Capital Reinvestment Ratio for CytomX Therapeutics Inc (2014–2020)

Year-by-year Capital Reinvestment Ratio for CytomX Therapeutics Inc from 2014 to 2020. See CytomX Therapeutics Inc (CTMX) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2020 0.44x $5.26 Million $2.31 Million ▲ +4698.2%
2017 0.01x $170.37 Million $1.56 Million ▼ -82.5%
2014 0.05x $31.80 Million $1.66 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow